바이오시뮬레이션 시장 : 기회, 성장 촉진요인, 산업 동향 분석(2025-2034년)

The Global Biosimulation Market reached USD 4.2 billion in 2024 and is projected to grow at an impressive CAGR of 17.7% between 2025 and 2034. Biosimulation, a cutting-edge approach in computational biology, leverages advanced mathematical models, sophisticated algorithms, and experimental data to replicate biological systems, processes, and interactions. This innovative technology delivers unparalleled insights into biological behavior under diverse conditions, supporting critical sectors such as drug discovery, clinical trial optimization, and personalized medicine development.

By enabling researchers to simulate complex biological processes with exceptional accuracy, biosimulation is transforming how therapies are developed, assessed, and optimized. Its role in reducing development costs, mitigating risks, and enhancing overall efficiency makes it a cornerstone of modern healthcare innovation. The growing demand for precision medicine and the increasing adoption of artificial intelligence and machine learning further amplify the significance of biosimulation in the healthcare and pharmaceutical industries.

The market is segmented based on offerings, including software and services. In 2024, the software segment dominated with a 62.4% share, driven by its ability to leverage machine learning and advanced algorithms for simulating intricate biological systems. Biosimulation software is available in two primary categories: integrated software suites/platforms and standalone modules. This technology empowers researchers by improving the prediction of drug efficacy and safety, enabling the identification of promising drug candidates earlier in the development cycle. This early identification accelerates the development process and significantly reduces associated costs, reinforcing the value of biosimulation in streamlining research and development operations.

Applications of biosimulation span multiple domains, with drug discovery leading the market in 2024, accounting for a 42.5% share. The drug discovery segment is anticipated to grow substantially, reaching USD 9.1 billion by 2034. Biosimulation enables the use of computational models to predict the behavior of potential drugs, minimizing the likelihood of costly late-stage failures. Researchers can simulate biological processes, refine molecular designs, and validate targets with precision, enhancing therapeutic efficacy and reducing time-to-market for new treatments. The ability to model complex interactions between drug candidates and biological systems is a game-changer, propelling the biosimulation market toward transformative advancements in healthcare.

The United States is set to remain a global leader in biosimulation innovation, with its market projected to reach USD 7.6 billion by 2034. The country's robust ecosystem, featuring premier research institutions and universities, underpins advancements in computational biology and biosimulation. The widespread adoption of precision medicine, which relies heavily on biosimulation to develop tailored therapies, further fuels market growth. The focus on personalized treatments based on genetic profiles ensures sustained demand for advanced biosimulation tools, strengthening the role of the U.S. in pioneering advancements across clinical and research applications.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° Synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic diseases
    • 3.2.1.2 Technological advancements in computational modeling
    • 3.2.1.3 Rising demand for personalized medicine
    • 3.2.1.4 Increasing use of AI and machine Learning
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs of biosimulation software and services
    • 3.2.2.2 Lack of skilled professionals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Offering, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Software
  • 5.2.1 Integrated software suites/platform
    • 5.2.1.1 Molecular modeling and simulation software
    • 5.2.1.2 Clinical trial design software
    • 5.2.1.3 PK/PD modeling and simulation software
    • 5.2.1.4 Pbpk modeling and simulation software
    • 5.2.1.5 Toxicity prediction software
    • 5.2.1.6 Other integrated software suites/platforms
  • 5.2.2 Standalone modules
• 5.3 Service

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drug discovery
• 6.3 Drug development
• 6.4 Disease modeling
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Therapeutic Area, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oncology
• 7.3 Cardiovascular disease
• 7.4 Neurological disorder
• 7.5 Infectious diseases
• 7.6 Other therapeutic areas

Chapter 8 Market Estimates and Forecast, By Delivery Model, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Subscription models
• 8.3 Ownership models
  • 8.3.1 License-based model
  • 8.3.2 Pay per use model
• 8.4 Service based models

Chapter 9 Market Estimates and Forecast, By Deployment Model, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 On premises model
• 9.3 Cloud based model

Chapter 10 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Pharmaceutical and biotechnology companies
• 10.3 Contract research organizations (CROs)
• 10.4 Academic research institutions

Chapter 11 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE

Chapter 12 Company Profiles

• 12.1 Allucent
• 12.2 Advanced Chemistry Development
• 12.3 Certara, USA
• 12.4 Cellworks
• 12.5 Chemical Computing Group
• 12.6 Dassault Systèmes
• 12.7 Genedata
• 12.8 In Silico Biosciences
• 12.9 Immunetrics
• 12.10 OpenEye
• 12.11 Physiomics
• 12.12 Simulations Plus
• 12.13 Schrödinger
• 12.14 Thermo Fisher Scientific
• 12.15 VeriSIM Life